Childhood Ependymoma Treatment (PDQ®)–Health Professional Version

Changes to This Summary (01/29/2019)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment of Newly Diagnosed Childhood Ependymoma, Anaplastic Ependymoma, or RELA Fusion–Positive Ependymoma

Revised text to state that the 3-year progression-free survival (PFS) rate for children treated with proton-beam radiation therapy was 76% in two series and appears to be similar to the PFS rate for children treated with intensity-modulated photon-beam radiation therapy. Also added text to state that in the two series that used proton-beam radiation therapy, the 3-year local control rates were 83% to 85%, with overall survival rates of 90% to 95% (cited Indelicato et al. as reference 19).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Recurrent Childhood Ependymoma

Next section >
About This PDQ Summary